ATG2B

Across TCGA pan-cancer cohorts, ATG2B mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of ATG2B’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where ATG2B mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types ATG2B is over-expressed in tumor, although a few such as CCRCC and PDAC show the opposite, repressed pattern.

CCRCC, PDAC, and LSCC are the cancer types where ATG2B tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ATG2B mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	All	IV	−0.422	<.001	12	view →
PDAC	Male	All	−0.562	<.001	8	view →
LSCC	All	All	−0.129	<.001	7	view →
OV	All	All	−0.336	.013	2	view →
LUAD	All	All	−0.067	.002	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

ATG2B–CCRCC

Open the CCRCC breakdown →